On September 8, the 26th China International Investment and Trade Fair (CIFIT) kicked off in grand style at the Xiamen International Expo Center. As a key brand section of this year’s CIFIT, the “Leading China · Emerging Industries” themed zone was established in Hall 5. The zone features beauty and wellness sectors, closely aligning with trends in medical aesthetics and health, wellness and healthcare consumption, and the integrated development of biotechnology and innovation. High-quality companies such as Kangzhijiandao and Sichuan Jiuzhang Biotechnology were invited to participate in the exhibition. Through technological innovation, they are empowering the upgrading of the wellness and new consumer industries, continuously unlocking new potential in the “beauty economy,” and driving the high-quality development of consumer industries that improve people’s livelihoods.

Jiuzhang Biotech has completed a Randomized, Controlled, Open-labeled, Multicenter Phase II/III Clinical Research on the Safety and Efficacy of the CHA for Injection for Recurrent Grade IV Glioblastoma (GBM). The company has also held EOPⅡ and pre‑Phase‑Ⅲ communication meetings with Chinese Center for Drug Evaluation, NMPA, reaching a consensus to proceed into Phase‑Ⅲ clinical trials.

CHA has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of malignant glioma. The designation was awarded on March 15, 2026, with Sichuan Jiuzhang Biotech. serving as the sponsor.

At the annual meeting of the European Society for Medical Oncology (ESMO) held in Berlin, Germany on October 20, 2025, Sichuan Jiuzhang Biotech Co., Ltd. gave an oral presentation on the study titled "A Randomized, Controlled, Open-labeled, Multicenter Phase II/III Clinical Research on the Safety and Efficacy of the CHA for Injection for Recurrent Grade IV Glioblastoma (GBM)". This study was successfully selected as a preferred project for the main venue of the conference.

On January 10, 2025, Sichuan Jiuzhang Biotech and Miskawaan Health Group (MHG) held an academic exchange in Bangkok focused on the mechanistic research of botanical medicines in the treatment of tumors, immune-related diseases, antioxidation, and integrative medicine.

This visit was led by Dr. Rawiwan Charoensub, a professor at the Faculty of Pharmacy and Director of the Center for Research and Development of Herbal Medicine of Mae Fah Luang University in Thailand. The members included Mr. Yoo Seung Kim and Ms. Kawinyarat Mardpiratchata, with a total of more than 20 people in the delegation. They explored the application prospects of herbal medicine in the fields of holistic treatment and functional medicine, and reached important consensus on future cooperation.